Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study.

Laham, R J; Chronos, N A; Pike, M; Leimbach, M E; Udelson, J E; Pearlman, J D; Pettigrew, R I; Whitehouse, M J; Yoshizawa, C; Simons, M

Laham, R J; Chronos, N A; Pike, M; Leimbach, M E; Udelson, J E; Pearlman, J D; Pettigrew, R I; Whitehouse, M J; Yoshizawa, C; Simons, M.

Affiliation

Laham RJ; Angiogenesis Research Center and Interventional Cardiology Section, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.

J Am Coll Cardiol ; 36(7): 2132-9, 2000 Dec.

Article in En | MEDLINE | ID: mdl-11127452

Subject(s)

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Fibroblast Growth Factor 2 / Myocardial Ischemia Type of study: Prognostic_studies Aspects: Patient_preference Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: J Am Coll Cardiol Year: 2000 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos

Search on Google

Add to My VHL

XML

PubMed Links